Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2–related Disease
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2020.05.21.109124: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Primary antibodies used included ACE2 (abcam-ab15348, 1:1000), EPCAM (abcam-ab228023, prediluted) and mouse anti-TMPRSS2 (Millipore-MABF2158, 1:500) and staining was performed as detailed in supplementary methods. ACE2suggested: Noneabcam-ab15348suggested: Noneabcam-ab228023suggested: Noneanti-TMPRSS2suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from Limita…SciScore for 10.1101/2020.05.21.109124: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Primary antibodies used included ACE2 (abcam-ab15348, 1:1000), EPCAM (abcam-ab228023, prediluted) and mouse anti-TMPRSS2 (Millipore-MABF2158, 1:500) and staining was performed as detailed in supplementary methods. ACE2suggested: Noneabcam-ab15348suggested: Noneabcam-ab228023suggested: Noneanti-TMPRSS2suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04320615 Completed A Study to Evaluate the Safety and Efficacy of Tocilizumab i… NCT04372186 Active, not recruiting A Study to Evaluate the Efficacy and Safety of Tocilizumab i… NCT04425538 Completed A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (C… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-